INTRODUCTION
There are an estimated 386,000 new cases of bladder cancer reported globally each year, with 150,000 deaths. 1 Approximately 70% of patients with bladder cancer present with nonmuscleinvasive cancer, with recurrence in 50% to 70% of cases and progression to muscle-invasive cancer in 10% to 20% of cases. 2 Active and passive tobacco exposure is the main risk factor for bladder cancer, followed by occupational exposure to benzene derivatives and arylamines. 3 Radical cystectomy with neoadjuvant chemotherapy is the standard therapy for muscle-invasive bladder cancer. 3 Treatment of nonmuscle-invasive bladder cancer, which includes pathology Stages Ta, T1, and Tis, is transurethral resection. Intravesical bacillus CalmetteGuérin immunotherapy is used to reduce recurrence and progression risk in these patients. 4 Intravesical treatment with mitomycin C has also been shown to reduce tumor recurrences and is used in the immediate postoperative period after resection of nonmuscleinvasive cancer. 5 Cystectomy should be considered for patients at high risk of recurrence and is indicated when intravesical bacillus Calmette-Guérin immunotherapy fails. 5 Whole plant extract of Viscum album (European mistletoe) contains a variety of immunoactive compounds with dosedependent cytotoxic activity and is used as adjuvant cancer therapy in Europe. 6, 7 The immunoactive compounds include mistletoe lectins, viscotoxins, and other low-molecular-weight proteins, including VisalbCBA (Viscum album chitinbinding agglutinin), oligosaccharides and polysaccharides, flavonoids, and triterpene acids. The whole plant extract and several of its compounds on their own are cytotoxic, and mistletoe lectins in particular have strong apoptosis-inducing effects. The antitumor activity of mistletoe lectins, including a prophylactic effect, has also been linked to their immunostimulatory effect, including in vitro and in vivo activation of monocytes/macrophages, granulocytes, natural killer cells, T cells, dendritic cells, and the induction of a variety of cytokines. 6, 8, [9] [10] [11] Furthermore, Viscum album extracts appear to interfere with tumoral angiogenesis. 6 A recent trial showed survival benefit in patients with advanced pancreatic cancer who were receiving Viscum album extracts, 12, 13 and durable tumor regression has been documented in case reports.
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High-Dose Viscum album Extract Treatment in the Prevention of Recurrent Bladder Cancer: A Retrospective Case Series
Most studies to date have tested the effects of low doses of Viscum album extract. 6, 7 However, more recently, clinicians have explored the use of high doses of the extract in light of its strongly dose-dependent cytotoxic activity 6, 7 and with the aim of increasing the immunostimulatory and fever-inducing effect of this treatment at initial doses. 8 Careful patient monitoring with high-dose treatment is important. Manufacturers recommend starting with the lowest strength, titrating upward until a mild fever and/or local inflammatory reaction occurs. Anaphylactic reactions to Viscum album extracts have been reported but are rare. 15 High-dose fever-inducing Viscum album extract treatment had a tumor-reducing effect in patients with advanced hepatocellular carcinoma. 16 Fever or hyperthermia has direct cytotoxic effects in human beings, activates antitumor immune mechanisms, and results in improved drug delivery to tumor sites through vasodilatation. 17 Tumor remissions in the context of febrile infections have been well documented, 18 which has led to the development of hyperthermia treatment for cancer. Combining intravesical hyperthermia treatment with intravesical mitomycin C treatment has been shown to reduce bladder cancer recurrence by 59%. 19 In a recent pilot study, hyperthermia treatment alone, when used before transurethral resection in patients with intermediate-to high-risk nonmuscle-invasive bladder cancer, resulted in 53% of patients showing complete tumor remission. 20 New targets for immunotherapy, beyond classic intravesical bacillus Calmette-Guérin immunotherapy, are also showing promising results. 21 However, to our knowledge, no studies have yet been done to explore the effect of high-dose, fever-inducing Viscum album extract treatment on bladder cancer recurrence. Therefore we did a retrospective analysis of the case notes of a series of patients with bladder cancer undergoing treatment with subcutaneous injections of high-dose Viscum album (Salicis, grown on willow trees) extract at one hospital outpatient clinic, to explore the effect of high-dose treatment on tumor recurrence.
METHODS
We reviewed the case notes of all patients with bladder cancer being treated at the outpatient clinic of the Alexander von Humboldt Klinik, Bad Steben, Germany. This hospital is a specialty center for high-dose Viscum album extract treatment. 22 Inclusion criteria were patients with confirmed, resectable (nonmuscle-invasive or muscleinvasive), urothelial bladder cancer who had undergone treatment with at least three injections of high-dose Viscum album (Salicis) extract between January 2006 and December 2012. We excluded patients who had had a cystectomy or those with advanced, inoperable bladder cancer. We reviewed patient data until December 31, 2013. Patients were contacted to verify their personal details, and we acquired written informed consent. We conducted brief interviews, which included exploration and documentation of patients' experiences during treatment with high-dose Viscum album extract treatment. Formal ethics approval was not required to carry out this case series. All patients were sent copies of our final analysis.
We calculated recurrence and progression risk in these patients using the European Organisation for Research and Treatment of Cancer (EORTC) risk tables. 23 In cases where patients had not responded to intravesical bacillus Calmette-Guérin immunotherapy, defined as recurrence of a high-grade tumor at 3 months after treatment, or recurrence after intravesical bacillus Calmette-Guérin immunotherapy, we used the progression risk of more than 25% after 5 years as reported by Davis et al. 24 We assessed the pattern of bladder cancer recurrence in included cases and categorized patients into 1 of 4 groups: likely beneficial effect, possible beneficial effect, unlikely beneficial effect, and not possible to assess. We considered high-dose Viscum album extract to have a likely beneficial effect when recurrence and progression risk was close to 100% and there was no more than 1 tumor recurrence after treatment. We considered there to be a possible beneficial effect when patients had no further recurrences 1 month after the start of treatment, tumor-free follow-up more than 30 months after treatment, and recurrence risk at time of treatment initiation between 62% and 78% (based on an EORTC score). We considered treatment to have an unlikely beneficial effect when patients had more than 1 recurrence after treatment. Patients with other circumstances explaining tumor nonrecurrence-for example, patients already tumor-free after another treatment or when tumor-free follow-up was less than 30 months-were categorized as not possible to assess.
For all included patients in this analysis, the treatment used was Iscucin Salicis (Wala Heilmittel GmbH, Bad Boll, Germany), an aqueous extract of Viscum album (European mistletoe) grown on willow trees (Salicis). Preparation involves extraction from freezedried whole plant with isotonic solution over 14 days without fermentation or heating, in accordance with methods reported in the German Homeopathic Pharmacopoeia (Rule 38). 25 One ampoule (1 mL) of a 1:20 concentration (5%, Strength H) contains 50 mg of the "mother extract" (including approximately 5.9 μg/mL of lectin, a key active ingredient) 26 ; concentration 1:400 (0.25%, Strength G) contains 2.5 mg; concentration 1:8000 (0.0125%, Strength F) contains 0.125 mg; and concentration 1:160,000 (0.000625%, Strength E) contains 0.00625 mg. Strengths F, G, and H fulfilled our criteria for high dose. Iscucin Salicis is licensed for the German market by the German Federal Institute for Drugs and Medical Devices.
For included patients in this series, the schedules of Viscum album extract treatment were individualized but followed general principles. All injections were given as 1-mL aqueous solutions subcutaneously in the lower aspect of the abdomen or upper part of the thigh. An initial dose of Iscucin Salicis at the highest strength, H (except Strength F in Case 2), was given in the outpatient clinic to observe reaction. Patients who responded with high fever and inflammatory reactions at the injection site received further injections, usually once
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High-Dose Viscum album Extract Treatment in the Prevention of Recurrent Bladder Cancer: A Retrospective Case Series weekly for 3 to 8 weeks. If no or little reaction occurred, injections were continued daily over 3 to 4 days to achieve the required inflammatory reaction. In patients with little or no reaction even after daily administration, Strength H was followed by weekly or twice-weekly injections of Iscucin Salicis Potency series II (a set containing Strengths D, E, F, and G) given in the order of 2×G, 2×F, 3×E, and 3×D and repeated over several months. One patient (Case 8) also received other types of Viscum album extract preparations.
Because the Alexander von Humboldt Klinik does not provide specialized urology services, all patients were followed up simultaneously by a private-practicing urologist or at a urology center.
CASE SUMMARIES
We identified eight patients who met our inclusion criteria: seven with nonmuscle invasive bladder cancer (pTa and pT1) and one with muscle-invasive bladder cancer (pT2a) who had refused cystectomy. Three cases are reported here in detail.
Case 1
A 59-year-old woman presented in February 2006 with 2 months of right-sided, colicky abdominal pain. Her medical history highlighted the removal of a uterine myoma and rightknee arthrosis with prosthetic replacement. She was a smoker (20 
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RESULTS
Tables 1a and 1b highlight the number of tumor recurrences and the outcomes for each patient. Reported tumors were removed by transurethral resection in all cases. Figure 1 shows a timeline of tumor recurrences and treatment for each patient.
Among the 8 patients, 28 episodes of recurrence were observed from diagnosis until December 2013 (median = 3.5 recurrences per patient; range = 1-6 per patient). After intravesical bacillus Calmette-Guérin immunotherapy or mitomycin C therapy (received by 7 patients), 12 episodes of recurrence occurred over 694 months of followup (median = 1.5 recurrences per patient; range = 0-4 recurrences; 5-year cumulative incidence = 1.0). Following initiation of treatment with high-dose Viscum album extract, 5 recurrences occurred over 523 months of follow-up (median = 0 recurrences per patient; range = 0-3 recurrences; 5-year cumulative incidence = 0.55). These outcomes were not comparable, however, because the interventions overlapped considerably. Among the 4 patients who received intravesical bacillus CalmetteGuérin immunotherapy, 2 patients had further recurrences but stopped having recurrences once Viscum album extract treatment was initiated (see The outcomes for each patient are described by category of effect.
Possible Beneficial Effect
• Case 1: The patient is 7 years tumorfree since the start of Viscum album extract treatment, after failure of intravesical bacillus Calmette-Guérin immunotherapy. This is a positive outcome for a patient for whom cystectomy was indicated.
• Case 2: The patient is 5 years tumorfree since the start of Viscum album extract treatment, despite frequent prior recurrences (including after intravesical bacillus Calmette-Guérin immunotherapy and mitomycin treatment) and a 78% recurrence risk. We did not define her recurrences as a failure of intravesical bacillus Calmette-Guérin immunotherapy because she had not received maintenance treatment.
• Case 3: The patient had frequent tumor recurrence despite mitomycin C treatment and is now 32 months tumor-free after Viscum album extract treatment.
• Case 6: This patient was at high risk of progression because of initial pT1 pathology. A Stage T1G1 tumor recurrence was detected within less than 1 month of initiation of Viscum album extract treatment; this recurrence could have been preexisting when treatment was started and therefore was not included in our analysis of recurrences. This patient went on to have a Stage pTis (carcinoma in situ) recurrence but is now 30 months tumor-free. • Case 8: This patient had a poor prognosis because of a diagnosis of muscle-invasive disease and refusal to have cystectomy and chemotherapy. A 12-week delay in cystectomy can reduce 3-year cancer survival to 35%. 27 The fact that she had only 1 nonmuscle-invasive recurrence and 5 years of tumor-free survival was therefore very unexpected, and we considered that Viscum album extract treatment together with intravesical bacillus Calmette-Guérin immunotherapy could have influenced the outcome in this patient. The effect of Viscum album extract treatment therefore seems likely, because her risk of recurrence and progression without cystectomy and chemotherapy was almost 100%. However, given the difficulty in attributing the effect to either intravesical bacillus CalmetteGuérin immunotherapy or Viscum album extract treatment, we conservatively rate the effect as a possible beneficial effect. This patient had a high-risk Stage pT1G3 tumor and five Ta recurrences, one of which was high-grade, despite radiochemotherapy. He then had seven years of tumor-free survival after two courses of intravesical bacillus Calmette-Guérin immunotherapy and Viscum album extract treatment, which we consider a very satisfactory outcome. We were unable to distinguish between the beneficial effect of intravesical bacillus Calmette-Guérin immunotherapy and Viscum album extract treatment because these treatments were given in relatively short succession after the last tumor recurrence. In summary, an effect from Viscum album extract treatment appeared to be a possibility in five patients (Cases 1, 2, 3, 6, and 8), could not be assessed in two cases (Cases 5 and 7), and was unlikely in one patient (Case 4).
Unlikely or Uncertain Beneficial Effect
Tolerability
Most patients experienced fever up to 40º C and local redness at the injection site (less than 5 cm in diameter in all cases) as part of the intended immune reaction. One patient had nausea and headache after using a particular additional Viscum album extract preparation, from a birch tree (Case 8). No patient needed to stop treatment because of side effects.
DISCUSSION
We present retrospective data from a series of eight patients with recurrent bladder cancer who had been treated with high-dose Viscum album extract treatment. Seven patients had nonmuscle-invasive cancers with frequently recurring tumors, one of whom had not responded to intravesical bacillus Calmette-Guérin immunotherapy; therefore, they were a difficult patient group to manage. Patients had either intermediate-risk or high-risk tumors, as defined by European guidelines. 5 One patient with muscle-invasive cancer had refused standard therapy, and so tumor recurrence and progression was almost certain. However, our analysis shows substantial and consistent decrease of recurrences in this series of patients. Despite unfavorable prognoses, we observed mainly positive outcomes after Viscum album extract treatment. Recurrences occurred in only three patients, and only one of those patients had three recurrences, and the patients had consistent, long, tumor-free periods subsequent to these recurrences, with no patient progressing. We therefore consider individual variation a less likely explanation, and a beneficial effect of Viscum album extract treatment as a possible explanation.
The analysis was not designed to compare recurrence incidence between intravesical bacillus CalmetteGuérin immunotherapy/mitomycin C treatment and Viscum album extract treatment. It also is not our intent to suggest management of muscle-invasive cancer without cystectomy. High-dose
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Few studies exist regarding the effect of Viscum album extract treatment in recurrence of bladder cancer. In one small study, intravesical treatment with lectin-standardized Viscum album extract seemed to have preventive effect at 12-month follow-up, similar to intravesical bacillus Calmette-Guérin immunotherapy-treated historical controls. 28 A small, prospective, randomized study in which low-dose, subcutaneous injections of lectin-standardized Viscum album extract were compared with no prophylactic intervention showed no benefit. 29 A randomized trial in 60 patients, comparing intravesical Viscum fraxini-2 with intravesical bacillus Calmette-Guérin immunotherapy found a recurrence rate of 73% vs 30%; muscle-invasive bladder cancer developed in 5 patients in each group. 30 A Phase 1b/2a dose-escalation study of intravesical treatment with Viscum album extract showed promising results 31 and is currently being followed by a Phase 3 study. 32 The treatment approach used in the patients in our case series differed from the approaches used in these other studies; the physicians at our clinic used subcutaneous application (more convenient than intravesical) and Viscum album extract grown on the willow tree (Salicis), which was selected on the basis of positive clinical experience. 33 A potential mechanism of action for Viscum album extract in preventing recurrence of bladder cancer is its known antitumor and immune-modulating activity and the potential beneficial effect of fever in cancer treatment as described earlier. 8, 15 We note, however, that Viscum album extract induced fever after the first 2 to 3 doses only and thus may not be considered fever therapy.
A recurring theme reported by patients in this case series was that the initially exhausting fever reaction was followed by a gain in energy and strength. This is consistent with systematic reviews on the beneficial effect on quality of life and cancer-related fatigue of Viscum album extract treatment. 6, 7 Some patients experienced the treatment as a turning point in their treatment course, after which they felt more confident that they had overcome the cancer. This report has several limitations. First, it is retrospective, and there are considerable differences among patients in terms of follow-up and treatment. Second, defining patients into certain categories after data mining is subject to researcher bias. Rather than a cohort, we present a series of individual cases, each assessed individually. The strengths of this report are that we provide direct observation from clinical practice, provide a qualitative judgment of each individual patient history, and have not merely provided an analysis of the best cases.
CONCLUSION
A prospective study is now needed to assess whether high-dose subcutaneous Viscum album (Salicis) extract can be an additional, bladder-sparing preventive option for patients with medium-to high-risk nonmuscle-invasive bladder cancer. v
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